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Ovarian tumours of low malignant potential (LMP) are intermediate between adenomas and ovarian carcinomas. These tumours are
often associated with a significantly better prognosis than ovarian carcinomas. However, a subset of these tumours can progress and
become lethal. In order to seek sensitive diagnostic tools for monitoring patients after surgical operation, we performed a genome-
wide scan for loss of heterozygosity (LOH) in 41 mucinous LMPs using 91 polymorphic microsatellite markers at an average interval
of 50cM across all of the human chromosomes and 25 LOH markers reportedly associated with ovarian carcinoma. In addition, we
assessed whether clinicopathological parameters, microvessel density, Ki-67 labeling index, apoptotic index or p53 overexpression
would be useful for predicting the postoperative outcome of LMP patients. Of the 116 markers examined, 19q12 and Xq11–12
showed significant correlation between postoperative progression-free survival time and LOH status (Po0.05). Patients with a high
Ki-67 labeling index had a significantly poorer progression-free survival time than those with lower levels (P¼0.042). Other
clinicopathological factors and immunohistochemical analysis had no correlation with progression-free survival time in this series of
patients. When the combination of LOH at 19q12 and/or Xq11–12 was assessed using Cox’s regression analysis, patients with
tumours that showed LOH at these positions were at greatest risk of progression (P¼0.0073). These findings suggest that the
identification of LOH at 19q12 and/or Xq11–12 in former mucinous LMP sites should alert the clinician to the presence of a
potentially aggressive lesion in the coelomic epithelium, even if a distinction between second primary tumours or recurrence could
not be determined.
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Ovarian carcinoma is the most lethal gynaecological malignancy at
present (Wingo et al, 1995). In 1929, Taylor first recognised the
existence of a group of ovarian carcinomas that were associated
with an improved prognosis; he termed these lesions ‘semimalig-
nant’ tumours (Taylor, 1929). In 1961, the International Federation
of Gynaecology and Obstetrics (FIGO) proposed a classification of
ovarian tumours that included low malignant potential (LMP)
lesions; this designation became effective in 1971 (FIGO, 1987) and
was incorporated into the World Health Organisation classification
in 1973 (Serov et al, 1973). Characterised by complex branching
papillae, epithelial stratification, nuclear atypia, mitotic activity,
and absence of stromal invasion, these tumours are considered to
be of LMP. Serous and mucinous tumours comprise the vast
majority of cases, with endometrioid, clear cell, and Brenner-type
tumours also described (Russel et al, 1994). Low malignant
potentials (30–50%) are mucinous type (Lee and Scully, 2000) and
the incidence of mucinous LMPs is high in Japan compared to
Western countries (Nakashima et al, 1990; Tamakoshi et al, 1997).
Mucinous LMPs present at earlier stages than invasive ovarian
carcinomas and have a more indolent long-term course and
excellent prognosis after surgical management alone (Tazelaar et al,
1985; Casey et al, 1993; Trimble and Trimble, 1994; Siriaunkgul
et al, 1995; Gershenson, 1999; Lee and Scully, 2000). Mucinous
LMP patients (60–85%) who present with stage I disease can be
managed conservatively with unilateral salpingo-oophorectomy
and complete staging. The postoperation 10-year survival rate is
93–99% for stage I disease (Casey et al, 1993; Trimble and
Trimble, 1994; Gershenson, 1999; Lee and Scully, 2000). For the
15–30% of patients who present with stage II–III disease, TAH-
BSO and surgical staging are the treatments of choice. Approxi-
mately 10–30% of these patients will relapse and 10% will die of
the tumour. The criteria for adjuvant chemotherapy for LMP
patients are still undetermined. An estimated 10% of patients will
develop ovarian carcinoma (Lee and Scully, 2000). Whether these
invasive secondary tumours represent progression of LMP to
invasive disease or new secondary tumours arising in at-risk
populations is still controversial (Siriaunkgul et al, 1995; Lee and
Scully, 2000). However, a subset of these tumours can progress and
become lethal. This poor outcome is largely due to a lack of
sensitive diagnostic tools for monitoring patients after surgical
operation, with a reliance upon clinical and pathological
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yparameters that are often difficult to assess for therapeutic
decision making. In the search for more reliable prognostic
indicators, a few investigators have focused on biological markers
that might be predictive of LMP development (Kaern et al, 1990;
Padberg et al, 1991). For example, Kaern et al (1990) reported that
DNA ploidy pattern was the most important prognostic marker in
their study. However, until now it has not been known which
molecular markers influence the fate of these patients, because
little is known about genetic alterations in LMPs. Among the
various types of genetic alterations involved in ovarian carcinoma
development and progression, loss of heterozygosity (LOH) of
particular chromosomal regions is thought to indicate the deletion
of a normally resident tumour suppressor gene (Callahan and
Campbell, 1989; Knudson, 1993). Thus, it is possible that the loss
of specific alleles may act as diagnostic markers of prognosis.
Recently, we reported that allelic loss could be a predictor of poor
outcome for ovarian carcinoma patients (Nakayama et al, 2003b).
In order to seek potential predictive markers in the current study,
we performed a genome-wide scan for LOH in 41 mucinous LMPs
using 91 polymorphic microsatellite markers at an average interval
of 50cM throughout all of the human chromosomes (screening
markers) and 25 LOH markers reportedly associated with ovarian
carcinoma (hotspot markers). In addition, we assessed whether
various clinicopathological parameters, microvessel density, Ki-67
labeling index, apoptotic index (AI), or p53 overexpression would
be useful for predicting the postoperative outcome of mucinous
LMP patients.
MATERIAL AND METHODS
Patients and tumour samples
In all, 41 mucinous LMPs and their adjacent non-neoplastic tissues
were obtained from archival pathological specimens at the
Institute of Japan Surgical Pathology and Seirei Hamatsu General
Hospital in Japan. Written informed consent for the analysis in
this study was obtained for each case individually. Diagnostic
verification and tumour subtyping and grading were performed
independently by three certified pathologists (TN, NT, and MF).
Low malignant potentials were diagnosed on the basis of
conventional histopathologic criteria (Serov et al, 1973), and
grading criteria recommended by the International Federation of
Gynecology and Obstetrics were used.
The ovarian origin of advanced-stage tumours was confirmed by
endoscopic examination, low levels of carcinoembryonic antigen,
and the clinical course, as well as by consultation with
gastrointestinal specialists of internal medicine and surgery, and
urologists. The present tumour tissues consisted of 41 mucinous
LMPs. There were 30 stage Ia patients, one stage Ib patients, eight
stage Ic patients, two stage II patients, and one stage III patient in
this study. Clinicopathological characteristics of these cases are
summarised in Table 1.
Unilateral salpingo-oophorectomy and TAH-BSO were per-
formed on patients who presented with stage I disease and with
stage II–III disease, respectively. None of the patients received
adjuvant chemotherapy. Follow-ups for all patients included in the
survival analysis were updated in January 25, 2003 (median follow-
up time was 103 months; range, 60–144 months). At that time, six
patients had progressed to well-differentiated ovarian carcinoma,
one patient had progressed to Pseudomyxoma peritonei, and 34
had not progressed.
DNA extraction
Paraffin-embedded tissues were sectioned at a thickness of 5mm
and stained with haematoxylin and eosin. The cancerous and non-
neoplastic portions were collected separately with a 29-gauge
needle using an MK1 micromanipulator (Singer Instruments,
Roadwater, UK) under a dissecting microscope (Figure 1). The
dissected tissue was collected in an Eppendorf tube and incubated
overnight at 581C in a digestion mixture (0.01 M NaCl; 0.5 M Tris-
HCl, pH 8.0; 20mM EDTA; 0.05% Tween-20R; 0.1mgml
 1
proteinase K). The samples were then heated to 951C for 10min
to inactivate the proteinase K activity. After the digestion, DNA
Table 1 Summary of clinical stage and histological subtype of LMPs
Stage
a
Histology Ia Ib Ic IIa IIb IIIc
Mucinous 30 1 7 1 1 1
aClinical staging was determined according to the International Federation of
Gynaecology and Obstetrics. LMP¼low malignant potential.
Figure 1 (A) An LMP tumour before microdissection ( 20, H&E).
Arrows indicate stromal cells and connective tissue. *, mucinous substrate
without cellular component. Scale bar, 25mm. (B) The LMP portion after
the removal of normal components. The LMP was collected for DNA
extraction ( 20, H&E). Arrows indicate removed stromal cells and
connective tissue. Scale bar, 25mm.
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precipitation. A representative example of LOH is shown in
Figure 2.
Microsatellite markers
We analysed LOH in LMPs with dye-labelled microsatellite
markers, including 25 markers for which LOH is reportedly
frequent in ovarian carcinoma (hotspot markers). Primer informa-
tion for the hotspot markers has been described previously
(Nakayama et al, 2001). Further LOH analysis in LMPs was carried
out with 91 markers located at an average distance of 50cM apart
and distributed throughout all of the human genome (screening
markers) (CHLC/Weber Human Screening Set 6A, Research
Genetics, Huntsville, AL, USA; primer information can be obtained
from K Nakayama).
PCR amplification and analysis of LOH
PCR reactions were performed in a total volume of 10ml containing
25–50ng of DNA, dNTPs at a final concentration of 20mM, 0.4mM
of each primer, and 0.25U of Ex-Taq DNA polymerase (Takara
Shuzo, Shiga, Japan) or Platinum Taq DNA polymerase (GIBCO
BRL, Rockville, MD, USA). After the mixture was heated for 10min
at 941C, PCR was performed for 45 cycles at 941C, at the
appropriate annealing temperature and at 721C for 1min each,
followed by 721C for 10min. After denaturation of the PCR
products at 941C for 2min, samples were subjected to electro-
phoresis using Performance Optimised Polymer 4 in a 310 Genetic
Analyzer (Applied Biosystems, Foster, CA, USA). Loss of hetero-
zygosity analysis was performed by Gene Scan version 2.1. Loss of
heterozygosity was quantitatively assessed by calculating the LOH
index, which was defined as the allele ratio in the normal tissue
divided by the allele ratio in the tumour tissue. The allele ratio was
calculated as the peak height of the smaller allele divided by the
peak height of the larger allele. If the LOH index was less than 0.5
or more than 2.0, we defined the case as LOH. The LOH frequency
of each locus was represented by the ratio of the number of cases
with LOH to the total number of informative cases.
Immunohistochemical analysis of p53, Ki-67, apoptosis
and microvessel density
Immunohistochemical analysis was conducted by avidin–biotin
complex method using 2.5-mm-thick sections from the paraffin-
embedded specimens. For the Ki-67 detection, anti-human MIB1
monoclonal antibody (MoAb) (Immunotech S.A., Marseille,
France) was used. After blocking the endogenous peroxidase
activity, the sections were heated for 20min in a microwave oven
at 500W to invigorate the antigens of the specimens, as reported
by Shi et al (1991) with slight modification. DO-7 and CD34
MoAb’s were used to immunostain p53 and microvessels in
ovarian carcinomas using the standard immunoperoxidase proce-
dure (Vectastain Elite ABC kit, Vector, Burlingame, CA, USA).
Immunostaining and evaluation of p53 and microvessel density
were performed as described previously (Nakayama et al, 2002,
2003a). Apoptotic cells were identified by terminal deoxynucleo-
tidyl transferase-mediated dUTP-biotin nick end-labelling (TU-
NEL) methodology, using the Apop Tag in situ detection kit
(Oncor, Gaithersburg, MD, USA). Terminal deoxynucleotidyl
transferase-mediated dUTP-biotin nick end-labelling methods
were performed as described previously (Hata et al, 2002). To
obtain the AI (the percentage of immunostained apoptotic tumour
cells) and Ki-67 labelling index (Ki-67 LI) (the percentage of
immunostained tumour cells), 1000 tumour cells were examined
by two observers (KN and YT).
Statistical analysis
Progression-free survival time was measured in months from the
month of surgery to the reported recurrence. Survival curves were
determined using the Kaplan–Meier method, and differences in
survival between subgroups were compared with the log-rank test.
P-values less than 0.05 were considered significant. All reported P-
values are two-sided.
RESULTS
LOH study
The frequency of LOH for each marker in informative tumours
ranged from 0 to 27.3%, with an average of 8.674.3%
(mean7s.d.). When 13% (meanþ1 s.d.) or more of the tumours
from informative cases showed LOH, we classified the LOH
frequency of the locus as significantly high. Among 116 loci, we
observed 22 loci with a significantly high LOH frequency (Table 2).
The most frequent LOH in mucinous LMPs was found at locus
D6S503 (6q27; 27.3%).
Clinicopathological factors and immunohistochemical
study
The following variables were examined for association with disease
progression by Kaplan–Meier methods: age (444 vs 44p); stage
(Ia vs Ibp); CA125 (354 vs 35p); and tumour size (15cm4 vs
15p) (Table 3). The mean AI of the 41 mucinous LMPs was 1.6%
(range, 0–5.6%; median, 1.3%). The proliferative activity of
tumour cells is described by the Ki-67 LI in each case. The mean
Ki-67 LI of the 41 mucinous LMPs was 28.0% (range, 0.6–77.4%;
median, 26.0%). The mean MVD of the 41 mucinous LMPs was
8.3% (range, 3.0–41.0%; median, 6.5%). Overexpression of p53 by
immunohistochemistry was observed in 4.2% (two of 41) of
analysed tumours. Concerning AI, Ki-67 LI, and MVD, we used the
median value (1.3, 26.0, and 6.5) as the optimal cutoff point to
divide the patients into two groups (Table 3). As the cases with
detectable p53 overexpression were rare, we used positive or
negative expression as the optimal cutoff point to divide the
patients into two groups.
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Figure 2 Representative example of LOH.
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Of the 116 markers examined, 19q12(D19S433) and Xq11–12 (AR)
showed significant correlation between postoperative progression-
free survival time and LOH status (Table 3). Kaplan–Meier
analysis of progression-free survival time revealed an increased
risk of postoperative progression in patients with tumours
exhibiting LOH at 19q12 and Xq11–12 compared to patients with
tumours that retained both alleles at these loci. As shown in
Table 1, we analysed the postoperative progression rate with
regard to LOH status at each of the loci, and carried out a log-rank
test to evaluate the statistical significance by univariate analysis.
None of the other 114 markers tested were correlated with
prognosis. Interestingly, these two loci were classified into the
significantly high LOH group (16.0%, four of 25, 17.6%, three of
17, respectively). Of the 41 patients with tumours informative at
19q12, 75% of those with LOH progressed within 5 years of
surgery, compared to a 5% progression rate among patients with
tumours that retained both alleles (P¼0.0023, Figure 3A). A
correlation between LOH and progression was also observed at
Xq11–12, with a 5-year progression rate of 67% in patients with
LOH and 5% in patients without LOH (P¼0.0122, Figure 3B).
Likewise, a combination of 19q12 and/or Xq11–12 revealed a 5-
year progression rate of 80% in patients with LOH and 4% in
patients without LOH (Po0.0001, Figure 3C). All comparisons
were significant (Table 3). In contrast, patients with a high Ki-67 LI
had a significantly poorer progression-free survival time than
those with lower levels (P¼0.042, Table 3). Other clinicopatho-
logical factors and immunohistochemical analysis had no correla-
tion with progression-free survival time in this series of patients
(Table 3). There was no significant difference in progression-free
survival time between intestinal and endocervical type (data not
shown). To determine whether these factors were prognostic
marker(s) independent of FIGO stage, an established prognostic
marker, we conducted a progression-free survival time analysis
using the Cox’s proportional-hazards model (Table 4). When the
combination of LOH at 19q12 and/or Xq11–12 was assessed,
patients with tumours who showed LOH at those positions were at
greatest risk of progression (P¼0.0073, Table 4).
DISCUSSION
Mucious LMPs are often associated with a significantly better
prognosis than mucinous ovarian carcinomas (Siriaunkgul et al,
1995; Pecorelli and Fallo, 1998; Lee and Scully, 2000). However,
gynaecologic oncologists have long sought prognostic markers that
could help to assess accurately the postoperative progression risk
in mucinous LMP patients, because a subset of these tumours can
progress and become lethal. For advanced stage mucinous LMPs,
earlier detection of a recurrence may not always result in improved
prognosis, due to the lack of efficacious chemotherapy (Tamakoshi
et al, 1997). However, in patients with early-stage tumours who
have been treated primarily with conservative surgery, earlier
detection of recurrence may result in better prognosis. Although
until recently routine postoperative decisions for mucinous LMP
patients rely on the consideration of conventional prognostic
factors such as clinical stage, recently, Winter et al (2002) reported
Table 2 Microsatellite marker loci demonstrating significant frequency
of LOH
Locus Localization LOH (%)
a
D2S427 2q36 6/26 (23.1)
D3S2403 3p25 4/18 (22.2)
D3S1764 3q21 3/22 (13.6)
D5S1473 5q14 5/24 (20.1)
D5S644
b 5q14–21 4/24 (16.6)
D5S1456 5q35 4/30 (13.3)
D6S300 6q14 3/23 (13.0)
D6S1003 6q24 3/11 (27.2)
D6S473 6q25 3/20 (15.0)
D6S1227 6q25 3/18 (16.7)
D6S503 6q27 3/11 (27.3)
D7S1805 7q35 6/31 (19.4)
D8S1119 8q21.2 4/27 (14.8)
D8S373 8q24.3 4/30 (13.3)
D9S922 9q21.32 4/25 (16.0)
D10S1435 10p15 3/21 (14.3)
TEL 12p12.3 4/23 (17.4)
NFI 17q11.2 5/26 (19.2)
D19S433
c 19q12 4/25 (16.0)
DXS6807 Xp22.3 3/13 (23.6)
DXS6797 Xq23 4/26 (15.4)
AR Xq11–12 3/17 (17.6)
aCases with LOH/informative cases.
bLoci shown in italic reveal that markers
reported to be associated with ovarian carcinoma.
cLoci shown in bold reveal that
tumour with LOH at these loci correlate with adverse outcome. LOH¼loss of
heterozygosity.
Table 3 Univariate analysis association of study variables with progres-
sion
Variables n Progression rate P-value
Age (years) 41
o44 20 0.15 0.3277
X44 21 0.19
Stage 41
Ia 30 0.03 o0.0001
XIb 11 0.45
CA125 41
o35 21 0.19 0.1527
X35 20 0.15
T (tumour size) 41
o15 23 0.13 0.7686
X15 18 0.22
MVD 21
High 21 0.33 0.9326
Low 20 0.15
Ki-67 LI 41
High 21 0.19 0.042
Low 20 0.13
Apoptotic LI 41
High 21 0.14 0.3489
Low 20 0.2
p53 overexpression 41
Positive 2 0.5 0.0559
Negative 39 0.15
19q12 LOH 25
LOH 4 0.75 0.0023
Retention 21 0.05
Xq11–12 LOH 17
LOH 3 0.67 0.0122
Retention 14 0.05
19q12 and/or Xq11–12 LOH 33
LOH 5 0.8 o0.0001
Retention 28 0.04
LOH¼loss of heterozygosity.
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between staged and unstaged patients who had surgery for LMP
patients. Only about half of all patients found to have LMPs
undergo complete surgical staging (Link et al, 1996). Removal of
the appendix is often included in the staging procedure for ovarian
carcinoma, including LMP lesions. The occurrence of synchronous
mucinous tumours of the ovary and appendix has been reported
(Young et al, 1991; Seidman et al, 1993; Prayson et al, 1994).
Recent studies of cytokeratin immunostaining patterns, clonality
studies with LOH, and molecular studies of K-ras mutations have
supported the conclusion that Pseudomyxoma peritonei usually
takes origin from the appendix and not the ovary (Guerrieri et al,
1995, 1997; Cuatrecasas et al, 1996; Szych et al, 1999). In the
current study, only one case had a recurrence as Pseudomyxoma
peritonei, but we diagnosed it as of ovarian origin because the
tumour was restricted to the left ovary and the appendix that was
dissected during the surgical operation was intact.
In the present study, we assessed immunohistochemical analysis
and various clinicopathological factors that could predict the
postoperative progression risk for mucinous LMP patients.
However, age, histology, CA125 levels, tumour size, MVD,
apoptotic LI, and p53 overexpression did not correlate with
postoperative progression rate. Previous studies have suggested
that DNA ploidy is prognostically important in mucinous LMP
patients (Kaern et al, 1990; Padberg et al, 1991). Kaern et al (1990)
and Padberg et al (1991) have correlated DNA aneuploidy with
increased tumour progression and shortened patient survival time.
In the present study, high Ki-67 LI was significantly associated
with tumour progression. Proliferative activity assessed by Ki-67
LI was significantly correlated with DNA aneuploidy in ovarian
neoplasm (Huettner et al, 1992). Therefore, Ki-67 LI may indirectly
reflect DNA aneuploidy in this series of mucinous LMPs.
Recently, specific LOH patterns have been implicated as
predictors of poor survival in various solid tumours (Choi et al,
2000; Hirano et al, 2001; Choi et al, 2002; Rosin et al, 2002;
Nakayama et al, 2003b). In the current study, of the 116 markers
examined only 19q12 and Xq11–12 showed significant correlation
between postoperative progression-free survival time and LOH
status (Table 3).
We found that patients whose tumours had shown LOH at 19q12
had a significantly shorter progression-free survival time than
those with retention of both alleles at 19q12. Although deletions of
chromosome 19q12 have been reported in head and neck
carcinoma, gliolbastoma, and astrocytoma, the association of
LOH at that region with poor survival has not been reported
previously (Nunn et al, 1999; Hu et al, 2002; Beder et al, 2003). We
speculate that a candidate tumour suppressor gene in the 19q12
region is associated not only with tumour progression but also
with an aggressive clinical phenotype.
At the genetic level, mucinous neoplasms show a characteristic
profile that is different from those of serous neoplasms. K-ras
mutation is highly characteristic of ovarian mucinous lesions, and
may indeed be the defining mutation that confers upon the lesion a
mucinous phenotype (Mandai et al, 1998). Schwartz et al (2002)
showed that mucinous ovarian carcinomas can be readily
distinguished from serous ovarian carcinomas based on their gene
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Figure 3 Kaplan–Meier curves for progression-free survival time of
patients with tumours that retained both alleles (retention) or that had lost
one allele (LOH) at a marker locus. LOH at 19q12 (A), at Xq11–12 (B),
and at 19q12 and/or Xq11–12 (C) was significantly associated with
progression-free survival time.
Table 4 Multivariate analysis of progression-free survival in LMP patients
Univariate Multivariate
Variables P-value
Hazard
ratio 95% CI P-value
Stage
Ia (n¼30) vs XIb (n¼11) o0.0001 4.5 1.0–20.4 0.0484
Ki-67 LI
High (n¼21) vs low (n¼20) 0.042 1.5 0.5–4.2 0.4351
19q12 and/or Xq11–12 LOH
LOH (n¼5) vs retention
(n¼28)
o0.0001 32.7 2.6–417.1 0.0073
LOH¼loss of heterozygosity; LMP¼low malignant potential.
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of tumour stage and grade (). Furthermore, the LOH profile of
mucinous LMPs is similar to that of mucinous ovarian carcinomas,
and in tumours showing LMP and invasive carcinoma compo-
nents, common LOH events have been demonstrated between the
LMP and carcinoma areas (Nakayama et al, 2001). These suggest
that mucinous LMPs in some cases progress to invasive
carcinomas. It has been suggested that deletions that include the
AR locus at Xq11.2–12 are involved in the development of both
LMP and ovarian carcinoma, including mucinous subtype
(Edelson et al, 1998). Thus, mucinous LMP tumours with LOH
at that region are precursors of mucinous ovarian carcinoma and
result in a poor clinical outcome. Since these two loci discussed
above were classified into the significantly high LOH group
(16.0%, four of 25, 17.6%, three of 17, respectively, Table 2) in the
present allelotype analysis, inactivation of a candidate tumour
suppressor gene around these regions could be crucial for the
tumourigenesis of mucinous LMP.
This study had several limitations. One limitation is that the
number of patients studied was relatively small because of the
logistics of long-term patient follow-up. Another limitation is that
Pseudomyxoma peritonei related to mucinous LMP that is more
likely to be associated with advanced stage, recurrence, and poor
prognosis (Nakashima et al, 1990; Casey et al, 1993) was included
in only one case in this study. A third limitation is that the
multifocality of metastatic disease was included only one case in
this study. The fourth limitation is that LMPs with microinvasion
was not included in this series of tumours. Larger studies with
more cases, including Pseudomyxoma peritonei and LMPs with
microinvasion, are needed to clarify the significance of LOH at
19q12 and Xq11–12.
In summary, the present study described for the first time the
use of microsatellite analysis to predict the poor outcome for
mucinous LMP patients. The results of our study suggest that the
identification of LOH at 19q12 and/or Xq11–12 in former
mucinous LMP sites should alert the clinician to the presence of
a potentially aggressive lesion in the coelomic epithelium, even if
the distinction between second primary tumours or recurrence
could not be determined.
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